Orexo launches underwritten rights issue of MSEK 250
Read more about Orexo Rights Issue at:
For further information, please contact:
Anders Lundström, President and CEO of Orexo
Tel: +46-18-780 88 12
E-mail: anders.lundströ[email protected]
Håkan Åström, Chairman of the Board of Orexo
Tel: +46-70-622 59 93
E-mail: [email protected]
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo’s registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. More information can be found at www.orexo.com.
Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on 4 May 2011 at 7.15.a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.